Aripiprazole (ABILIFY®) Approved For The Treatment Of Moderate To Severe Manic Episodes In Bipolar I Disorder In Adolescents

Otsuka Pharmaceutical Co., Ltd. announced today that the European Medicines Agency (EMA) has approved a label extension for aripiprazole for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 and older. � This will be the first centrally approved indication for the treatment of moderate to severe manic episodes in Bipolar I Disorder in this age group in Europe...
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Bipolar Source Type: news